PTO/IS6/64 (10:05) Approved for use through 07/31/2006 OMB 0651-0051

U.S. Patent and Trademark Officer, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number  DETITION FOR REVIVAL OF AN ADDITION FOR PATENT   Docket Number (Optional)				
	ON FOR REVIVAL OF AN APPLICATION FOR ONED UNINTENTIONALLY UNDER 37 CFR 1.		SSL0102 US PCT	
ADANU	ONED DIVINI ENTITIONALLY UNDER 37 CFR 1	.137(0)	3350102 531 61	
First name	ed inventor: ARANYI, et al		***************************************	
Application	n No.: 10/518,114	Art Unit:	1624	
Filed: M	larch 21, 2005	Examiner:	LEESER, Erich	
Title: Co	OMPOUNDS			
Attention: Office of Petitions  Mail Stop Petition  Commissioner for Patents P.O. Box 1450  Alexandra, VA 22313-1450  FAX (571) 273-8300				
NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (571) 272-3282.				
The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained.				
APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION				
NOTE: A grantable petition requires the following items:  (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and (4) Statement that the entire delay was unintentional.				
Nettiton fee     Small entity-fee \$ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.				
Other than small entity – fee \$ 1520.00 (37 CFR 1.17(m))				
Reply and/or fee     A. The reply and/or fee to the above-noted Office action in the form of RCE, IDS with 1 reference				
	has been filed previously on is enclosed herewith.		*	
-	The issue fee and publication fee (if applicable) of \$ has been paid previously on is enclosed herewith.		············	

This collection of information is required by 37 CFR 1.137(b). The information is required to occur or retain a benefit by the public when is to fifs used by the USETTO is accessed an adjoinance. Confidentiating in governor by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to taken it have been used to be a confidentiating the confidentiating the confidentiation of the confidentiation of

PTO/SR64 (\$0.6)
Approved for use through 07/61/2008, 0466 9669-0031
U.S. Peldent and Trademank Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless & displays a valid OMS control number

3. Terminal disclaimer with disclaimer fee				
Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.				
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see				
PTO/SB/63).  A STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).]				
WARNING:				
Pestioneriapplicant is autioned to avoid submitting personal information in documents filed in a patient application that may contribute to identity their. Personal information such as social security numbers, bank account numbers correctly card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO is support a petition or an application. If this type of personal information is included in documents submitted to USPTO, petitioner/applicants should consider redacting such personal information is included in documents submitting them to the USPTO. Petitioner/applicant is advised that the record of a patient application is evailable to the public after publication of the application (unless a non-publication request in compliance with 37 CPR L13(a) is made in the application is referenced in a published application or an issued patient (see 37 CPR L14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.				
/ Brian R. Morrill /	January 22, 2010			
Signature	Date			
Brian R. Morrill	42,908			
Typed or printed name	Registration Number, if applicable			
sanofi-aventis	908-231-5705			
Address	Telephone Number			
Route 202-206, P.O. Box 6800,				
Address				
Meil Code D-303A, Bridgewater, NJ 08807				
Address				
Enclosures: Fee Payment				
Reply				
Terminal Disclaimer Form				
Additional sheets containing statements establishing unintentional delay				
✓ Other: RCE, IDS with 1 reference				
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]  I hereby certify that this correspondence is being:  Deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.  Transmitted by facsimile on the date shown below to the United States Patent and Trademark Office as (571) 273-8300.				
January 22, 2010				
Date Signature				
-	Typed or printed name of person signing certificate			